Ruxolitinib Cream Approved for Children Aged 2-11 With AD

Ruxolitinib is the first topical JAK inhibitor approved in the US for pediatric AD.
Medscape Medical News

Source link : https://www.medscape.com/viewarticle/ruxolitinib-cream-approved-children-aged-2-11-atopic-2025a1000ow3?src=rss

Author :

Publish date : 2025-09-19 05:22:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

Ruxolitinib Cream Approved for Children Aged 2-11 With AD

Doctor sexual misconduct hearings too lenient, says UK review

Gene Therapy Shows Signal for Improving Retinal Function

Related Posts

Pain Patients Often Feel Out of Options. Acupuncture Hides in Plain Sight.

Trump and Republicans Once More Face a Tough Political Fight Over Obamacare

Extinct animals in Prehistoric Planet: Ice Age make it a must-watch

‘It sounds dramatic – but singing class saved by life’

Is Chemo Driving Late Cardiac Events in Older Cancer Survivors?

Potassium in Patients with ICDs; mRNA Flu Vaccine; Canceled NIH Funding for Trials

Pain Patients Often Feel Out of Options. Acupuncture Hides in Plain Sight.

Trump and Republicans Once More Face a Tough Political Fight Over Obamacare

Extinct animals in Prehistoric Planet: Ice Age make it a must-watch

‘It sounds dramatic – but singing class saved by life’

Is Chemo Driving Late Cardiac Events in Older Cancer Survivors?

Potassium in Patients with ICDs; mRNA Flu Vaccine; Canceled NIH Funding for Trials

The FDA Commissioner Is Missing the Point of Advisory Committees

MAHA Idealism Meets Political Reality as RFK Jr. Seeks to Wrangle Growing Movement

Categories

Archives